| Execution period | Vesting over 1-4 years; exercise period of 4 years from vesting |
|---|
BSE filing, NSE: WINDLAS. Summary written from the filing by ALFA Finder's alert engine.
Windlas Biotech Ltd: key numbers
- Share price
- ₹998.35
- Market cap
- ₹2,095 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.
Other employee stock options announcements
All →Axis Bank Employee Stock Options
Axis Bank allotted 220,144 equity shares on November 11, 2026, under its ESOP/RSU scheme. The paid-up capital increased, with no cash value stated for the allotment.
Regency Fincorp Employee Stock Options
Regency Fincorp instituted ESOP 2026, granting a pool of 1 crore employee stock options. Each option converts into one equity share at a market-linked exercise price.
- Execution
- Exercise period of up to 10 years from each vesting date
eClerx Services Employee Stock Options
eClerx's Employee Welfare Trust bought 11,825 shares and sold 11,059 shares on NSE on 6 and 9 November 2026. Net holding moved only slightly, from 2.49% to 2.48%.
- Value
- ₹1.89 Cr
Virtuoso Optoelectronics Employee Stock Options
Virtuoso Optoelectronics granted up to 4,40,000 options under ESOP 2023 at up to Rs 468.55 each. Nomination and Remuneration Committee approved the grant on 10 November 2026.
Stove Kraft Employee Stock Options
Stove Kraft granted 97,519 stock options to eligible employees under its ESOP Plan 2018 at ₹789.35 per option. The grant vests over four years, with no cash proceeds received at grant.
- Execution
- Vesting over 4 years: 10% at 1st anniversary, 20% at 2nd, 30% at 3rd, 40% at 4th; exercisable within 4 years of vesting.
RBL Bank Employee Stock Options
RBL Bank allotted 1,85,172 equity shares to employees on 9 November 2026 on exercise of vested ESOPs. Paid-up capital rises to Rs 1,552.99 Crore.